IDiyas

For the Inventor, By the Inventor

San Diego, CA, United States of America

Holly Reichard

USPTO Granted Patents = 24 

 

 

Average Co-Inventor Count = 6.4

ph-index = 4

Forward Citations = 41(Granted Patents)


Company Filing History:

goldMedal24 out of 1,177 
 
Takeda Pharmaceutical Company Limited
 patents

Years Active: 2015-2025

where 'Filed Patents' based on already Granted Patents

24 patents (USPTO):
1. 12370192 - Azole-fused pyridazin-3(2H)-one derivatives (2025-07-29),
2. 11173161 - 4-oxo-3,4-dihydro-1,2,3-benzotriazine modulators of GPR139 (2021-11-16),
3. 10738046 - Substituted pyrido[3,4-b]pyrazines as GPR6 modulators (2020-08-11),
4. 10597392 - Tetrahydropyridopyrazines as modulators of GPR6 (2020-03-24),
5. 10561662 - 4-oxo-3,4-dihydro-1,2,3-benzotriazine modulators of GPR139 (2020-02-18),
6. 10407443 - 5-HT3 receptor antagonists (2019-09-10),
7. 10406157 - Tetrahydropyridopyrazine modulators of GPR6 (2019-09-10),
8. 10273225 - Pyrazines as modulators of GPR6 (2019-04-30),
9. 10179783 - Tetrahydropyridopyrazines as modulators of GPR6 (2019-01-15),
10. 10159677 - 4-OXO-3,4-dihydro-1,2,3-benzotriazine modulators of GPR139 (2018-12-25),
11. 10125145 - 5-HT3 receptor antagonists (2018-11-13),
12. 10077266 - Substituted pyrido[3,4-b]pyrazines as GPR6 modulators (2018-09-18),
13. 10000468 - Pyrazines as modulators of GPR6 (2018-06-19),
14. 9770452 - Quinoxaline derivatives as GPR6 modulators (2017-09-26),
15. 9770450 - 4-OXO-3,4-dihydro-1,2,3-benzotriazine as modulators of GPR139 (2017-09-26),

Title: The Innovative Contributions of Holly Reichard in Pharmaceutical Development

Introduction

Holly Reichard, based in San Diego, CA, is a prominent inventor recognized for her significant contributions to the field of pharmaceuticals. With an impressive total of 23 patents, Holly has demonstrated her commitment to innovation and the advancement of medical treatments.

Latest Patents

Holly’s latest patents reflect her focus on novel compounds relevant to receptor modulation. One of her notable inventions is related to “4-oxo-3,4-dihydro-1,2,3-benzotriazine modulators of GPR139.” This invention outlines a method for treating diseases associated with GPR139 by utilizing specific compounds as agonists. It also includes the pharmaceutical compositions, processes for synthesizing these compounds, and the necessary intermediates.

Another significant patent features “Substituted pyrido[3,4-b]pyrazines as GPR6 modulators.” This patent provides a new class of compounds that are useful as modulators of GPR6, alongside pharmaceutical compositions, methods for treating related conditions, and the synthesis processes of these compounds.

Career Highlights

Holly is currently affiliated with Takeda Pharmaceutical Company Limited, where she leverages her expertise to develop groundbreaking treatments. Her work has notably influenced drug discovery and development, paving the way for innovative therapies in various therapeutic areas.

Collaborations

Throughout her career, Holly has worked alongside esteemed colleagues such as Holger Monenschein and Stephen A Hitchcock. Their collaborative efforts have enhanced the research landscape in receptor modulation and have been crucial in advancing the understanding of various drug targets.

Conclusion

Holly Reichard's innovative spirit and dedication to her work have made her a key figure in the pharmaceutical industry. With her ongoing research and numerous patents, she continues to contribute significantly to medical science, ultimately improving patient outcomes through innovative drug development.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…